Anteris CEO to Present at Three Major Healthcare Investor Conferences in September
Event summary
- Anteris CEO Wayne Paterson will present at three healthcare investor conferences in September 2026.
- Presentations include fireside chats and 1x1 meetings at Cantor, Wells Fargo, and Morgan Stanley conferences.
- DurAVR® Transcatheter Heart Valve is Anteris' lead product for treating aortic stenosis.
- ADAPT® tissue technology has been used in over 55,000 patients worldwide.
The big picture
Anteris' participation in these high-profile investor conferences underscores its strategic focus on expanding market awareness and securing investor confidence. The cardiovascular device market is highly competitive, with significant emphasis on innovation and clinical outcomes. Anteris' DurAVR® THV, designed to mimic healthy aortic valve function, positions the company as a key player in treating aortic stenosis, a condition affecting millions globally. The upcoming presentations will be critical in shaping the company's narrative and investor expectations.
What we're watching
- Market Positioning
- How Anteris will leverage these conferences to strengthen its position in the competitive cardiovascular device market.
- Investor Sentiment
- Whether the presentations will shift investor perception of Anteris' growth prospects and technological edge.
- Product Adoption
- The pace at which DurAVR® THV gains traction among interventional cardiologists and cardiac surgeons.